Daiichi Sankyo Europe GmbH

Daiichi Sankyo and its 15.000 employees in more than 20 countries are dedicated to the creation and supply of innovative pharmaceutical products. The group’s 2025 vision is to become a “Global Pharma Innovator with Competitive Advantage in Oncology”. Our research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology. Our European headquarters are in Munich, Germany and we have affiliates in 12 European countries. For more information: www.daiichi-sankyo.eu.